Previous 10 | Next 10 |
HIGHLANDS RANCH, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-mo...
Vivos Therapeutics (VVOS) has priced its follow-on public offering of 4M shares of common stock at $6.00/share, for expected gross proceeds of $24M.Underwriters' over-allotment is an additional 600K shares. Roth Capital Partners is acting as sole book-running manager. National Securities Corp...
HIGHLANDS RANCH, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-mo...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment ...
HIGHLANDS RANCH, Colo., April 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-diso...
In this episode of Industry Focus: Wildcard , join Motley Fool contributor Brian Feroldi and host Emily Flippen as they talk about three companies trying to treat sleep apnea: ResMed (NYSE: RMD) , Inspire Medical (NYSE: INSP) , and Vivos Therapeutics (NASDAQ: V...
Gainers: Chembio Diagnostics CEMI +60%, Nano-X Imaging NNOX +25%, NanoVibronix (NAOV) +16%, Vivos Therapeutics (VVOS) +15%, Greenwich LifeSciences (GLSI) +14%.Losers: Molecular Templates (MTEM) -26%, ACADIA Pharmaceuticals ACAD -17%,...
Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...
HIGHLANDS RANCH, Colo., March 30, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-diso...
Vivos Therapeutics (VVOS): FY GAAP EPS of -$1.40 misses by $0.93.Revenue of $13.07M (+14.7% Y/Y) beats by $0.13M.Shares +3.22%.Press Release For further details see: Vivos Therapeutics EPS misses by $0.93, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Vivos Therapeutics Inc. Company Name:
VVOS Stock Symbol:
NASDAQ Market:
Vivos Therapeutics Inc. Website:
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS) , a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments f...
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) i...
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment Sponsored by Seneca Partners, Who Will Also Provide General Management Advisory ...